# Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

> **NCT06434363** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 47 (estimated)

## Conditions studied

- Autoimmune Disorders
- Systemic Sclerosis
- Systemic Lupus Erythematosus
- Lupus
- Lupus Nephritis

## Interventions

- **DRUG:** Tafasitamab
- **DRUG:** Fludarabine phosphate
- **DRUG:** Cyclophosphamide
- **DRUG:** Tafasitamab and NK cells

## Key facts

- **NCT ID:** NCT06434363
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-31
- **Primary completion:** 2028-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06434363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06434363, "Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT06434363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*